Prescriber's Corner

Pertuzumab in Metastatic Breast Cancer

Rachana Patel, PharmD, BCPS, and Jill S. Bates, PharmD, MS, BCOP

From WakeMed Health and Hospitals, Raleigh, North Carolina, and University of North Carolina Hospitals, Chapel Hill, North Carolina

The authors have no conflicts of interest to disclose.

Correspondence to: Rachana Patel, PharmD, BCPS, 101 Manning Drive, Chapel Hill, NC 27514. E-mail: rppatel05@yahoo.com


J Adv Pract Oncol 2012;3:391–394 | DOI: 10.6004/jadpro.2012.3.6.5 | © 2012 Harborside Press®


  

ABSTRACT

Pertuzumab (Perjeta) is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer. Read about key trials that led to its approval, its adverse event profile, and other implications for the AP in oncology.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.